2013 DRAFTING REQUEST

| Senat | te Amei | ndment | (SA-SB49 | 8) | | | | |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------|-------------------|----------------------|---------|----------------------|----------------------|----------|
| Receiv | red: | 2/11/2014 | | | | Received By: | mgallagh | |
| Wantee | d: . | As time permits | | | | Same as LRB: | a1814 | |
| For: | For: Paul Farrow (608) 266-9174 | | | | | By/Representing: | Scott R. | |
| May Contact: | | | | | | Drafter: | mgallagh | |
| Subjec | et: | Trade Re | gulation - o | ther | | Addl. Drafters: | | |
| | | | | | | Extra Copies: | MDK | |
| Reques | Submit via email: Requester's email: Carbon copy (CC) to: YES Sen.Farrow@legis.wisconsin.gov michael.gallagher@legis.wisconsin.gov | | | | | | | |
| Pre To | - | topic give | en | | | | | |
| Topic | * | | | | | | | |
| Variou | ıs exemp | otions | | | | | | |
| Instru See att | ections: | | | | | | | |
| Drafti | ing Histo | ory: | | | | | | |
| Vers. | <u>Drafted</u> | <u> </u> | Reviewed | Typed | Proofed | Submitted | <u>Jacketed</u> | Required |
| /? | mgallag 2/12/20 | | dyer 2/12/2014 | | | | | |
| /1 | mgallag 2/13/20 | | dyer 2/13/2014 | jmurphy 2/12/2014 | | lparisi 2/12/2014 | lparisi 2/12/2014 | |

/2

mgallagh 2/19/2014 jdyer 2/19/2014 jfrantze 2/13/2014 sbasford

2/13/2014

sbasford

2/13/2014

LRBa1730 2/19/2014 9:24:15 AM Page 2

| Vers. | <u>Drafted</u> | Reviewed | Typed | Proofed | Submitted | <u>Jacketed</u> | Required |
|-------|----------------|----------|-----------------------|---------|-----------------------|-----------------------|----------|
| /3 | | | rschluet 2/19/2014 | | sbasford 2/19/2014 | sbasford 2/19/2014 | |
| FE Se | nt For: | | | | | | |

<END>

2013 DRAFTING REQUEST

| Senate | e Amendme | ent (SA-SB49 | 8) | | | | |
|---------|-------------------------------------------------|--------------------|-----------------------------|----------------|----------------------|---------------------------------------|----------|
| Receive | ved: 2/11/2014 | | |] | Received By: | mgallagh | |
| Wanted | l: As tin | ne permits | | ; | Same as LRB: | | |
| For: | Paul I | Farrow (608) 26 | 6-9174 | | By/Representing: | Scott R. | |
| May Co | ontact: | | | Drafter: | mgallagh | | |
| Subject | t: Trade | e Regulation - o | ther | , | Addl. Drafters: | | |
| | | | | | Extra Copies: | MDK | |
| Reques | t via email: ster's email: 1 copy (CC) to | | rrow@legis el.gallagher(| | | | |
| Pre To | pic: | | ANIMA | | | | |
| No spe | ecific pre topic | given | | | | | |
| Topic | : | A House | | | | | |
| Variou | is exemptions | / | | | | | |
| Instru | ictions: | | | | 10,00 | A A A A A A A A A A A A A A A A A A A | |
| See att | tached | | | | | | |
| Drafti | ing History: | | | | | | |
| Vers. | Drafted | Reviewed | Typed | Proofed | Submitted | Jacketed | Required |
| /? | mgallagh 2/12/2014 | jdyer 2/12/2014 | | | - | | |
| /1 | mgallagh 2/13/2014 | jdyer 2/13/2014 | jmurphy 2/12/2014 | | lparisi 2/12/2014 | lparisi 2/12/2014 | |
| /2 | / | 379 ic | jfrantze 2/13/2014 | n 4 | sbasford 2/13/2014 | sbasford 2/13/2014 | |

| FE | Sent | For: |
|----|------|------|
| | | |

<END>

2013 DRAFTING REQUEST

| Senate | e Amer | dment (S | A-SB49 | 8) | | | | |
|---------|--------------------------------------|--------------|--------------|-------------------------------|-----------------------------------------|--------------------------|----------------------|----------|
| Receive | ed: 2 | 2/11/2014 | | | | Received By: | mgallagh | |
| Wanted | i : A | As time peri | mits | | | Same as LRB: | | |
| For: | I | Paul Farrov | v (608) 26 | 66-9174 | | By/Representing: | Scott R. | |
| May Co | ontact: | | | | | Drafter: | mgallagh | |
| Subject | t: 1 | Гrade Regu | lation - o | ther | | Addl. Drafters: | | |
| | | | | | | Extra Copies: | MDK | |
| Reques | t via ema ster's ema n copy (C | ail: | | nrow@legis.vel.gallagher@ | | | | |
| Pre To | pic: | | | | | | | |
| No spe | ecific pre | topic given | | | | | | |
| Topic: | | | | | | • | | |
| Variou | is exemp | tions 🗸 | | | | | | |
| Instru | ctions: | | | | | | ,, | |
| See att | ached | | | | | | | |
| Drafti | ng Histo | ory: | | | , , , , , , , , , , , , , , , , , , , , | | | |
| Vers. | Drafted | Re | viewed | Typed | Proofed | Submitted | <u>Jacketed</u> | Required |
| /? | mgallag 2/12/20 | | er 2/2014 | | | - - | | |
| /1 | | /2, | 13 jc | jmurphy) 2/12/2014 | Hoi | _ lparisi _ 2/12/2014 | lparisi 2/12/2014 | , |
| FE Sei | nt For: | | | | 3/1 | 3 | | , |

<**END>**

2013 DRAFTING REQUEST

| Senate Am | endment (SA | A-SB498) | | | | | | |
|-----------------------------------------------|----------------------------|-----------------------------------------|---------|-----------------------|-----------------|----------|--|--|
| Received: | 2/11/2014 | | I | Received By: mgallagh | | | | |
| Wanted: | As time perm | nits | S | Same as LRB: | | | | |
| For: | Paul Farrow (608) 266-9174 | | | By/Representing: | Scott R. | | | |
| May Contact | : | | I | Drafter: | mgallagh | | | |
| Subject: | Trade Regula | ation - other | A | Addl. Drafters: | | | | |
| | | | I | Extra Copies: | MDK | | | |
| Submit via er Requester's e Carbon copy | mail: | YES Sen.Farrow@le michael.gallagh | | | | | | |
| Pre Topic: | | | | | | | | |
| No specific p | re topic given | | | | | | | |
| Topic: Various exen | nptions, 01 | | | | | | | |
| Instructions | • | | | | | | | |
| See attached | | | | | | | | |
| Drafting His | story: | | | | | | | |
| Vers. Drafte /? mgall | - / 1 / | ewed Typed | Proofed | Submitted | <u>Jacketed</u> | Required | | |

<END>

FE Sent For:

Gallagher, Michael

From:

Gallagher, Michael

Sent:

Tuesday, February 11, 2014 12:31 PM

To:

Rausch, Scott

Subject:

RE: Amendments to LRB 29996/1; Senate Bill 498 and Assembly Bill 656 relating to Patent

Trolls

This looks like it should be a simple, not a substitute amendment. If it looks more extensive after I start drafting, I'll double back.

Mike

Mike Gallagher

Attorney

Wisconsin Legislative Reference Bureau

(608) 267-7511

From: Rausch, Scott

Sent: Tuesday, February 11, 2014 12:30 PM

To: Gallagher, Michael

Subject: RE: Amendments to LRB 29996/1; Senate Bill 498 and Assembly Bill 656 relating to Patent Trolls

Yes, if it is easier to do a sub amendment, then we can offer a substitute.

Scott Rausch

Chief of Staff
Office of Senator Paul Farrow
(608) 266-9174
Scott.Rausch@legis.wi.gov

From: Gallagher, Michael

Sent: Tuesday, February 11, 2014 12:27 PM

To: Rausch, Scott

Subject: RE: Amendments to LRB 29996/1; Senate Bill 498 and Assembly Bill 656 relating to Patent Trolls

Okay. It looks like you want one amendment with the three exemptions, not three separate amendments, right?

Mike Gallagher

Attorney

Wisconsin Legislative Reference Bureau

(608) 267-7511

From: Rausch, Scott

Sent: Tuesday, February 11, 2014 12:22 PM

To: Gallagher, Michael

Subject: Amendments to LRB 29996/1; Senate Bill 498 and Assembly Bill 656 relating to Patent Trolls

Michael,

We have a few amendments to the Patent Troll bill. Bear with me, there are a lot of moving parts with this request.

I have amendment requests from pharmaceutical companies, the University of Wisconsin, and Bio-tech companies. I want to ease all of their concerns.

Attached you will find a document relating to the Virginia model legislation on patent trolling. On page two, in the highlighted section, you will see the language that we believe will ease the concerns of pharmaceuticals.

UW would like an exemption as well, and the example of their request is a follows:

This would go into the new section of the draft that lays out exemptions: (1) The person is an institution of higher education or a technology transfer organization owned or affiliated with an institution of higher education.

BioForward would also like an exemption for medical devices.

The following may clear up the requests for all three:

"Exemption.—A patent notification sent by the following shall not be subject to the provisions of this Act:

- 1) A person that is an institution of higher education or a technology transfer organization owned or affiliated with an institution of higher education; or
- 2) A person sending the patent notification to a target that has filed an application to the FDA or USDA for approval of a medical device; or
- 3) A person sending the patent notification to a target for a claim for relief arising under 35 U.S.C. § 271(e)(2) or 42 U.S.C. § 262."

Sub 3 is the same language from Pharma in the attached document.

Sub 1 ensures that WARF and other public entities (like the Medical College of Wisconsin) that are held to greater levels of accountability are exempted as requested.

Sub 2 provides an exemption when the underlying patents are used in medical devices that require approval by the FDA and USDA as requested by BioForward. This language does not exempt a person from attempting to unfairly enforce the underlying patents to the extent they are NOT used in medical devices that require approval from the FDA or USDA. As an example, a patent covering a processor used in a MRI machine would be exempted when it is asserted against another who is trying to use the same processor in an MRI to be approved by the FDA, but it would not be exempted when it is asserted against a print control system, phone, or non-medical device technology, etc.... This makes sense because of the greater level of oversight for those regulated industries like medical devices and pharmaceuticals but still protects those Wisconsin companies that are not subject to those federal requirements.

I hope this information is clear. If you have any questions please let me know. I can run your questions passed interested parties.

Thank you for your attention to these amendment requests.

Scott Rausch

Chief of Staff
Office of Senator Paul Farrow
(608) 266-9174
Scott.Rausch@legis.wi.gov

Gallagher, Michael

From:

Rausch, Scott

Sent:

Tuesday, February 11, 2014 12:23 PM Gallagher, Michael

To:

attachement

Subject: Attachments:

VA HB375 Patent Troll with amendment.pdf

Attachment....

Scott Rausch

Chief of Staff Office of Senator Paul Farrow (608) 266-9174 Scott.Rausch@legis.wi.gov

3

4

8

10 11

12

13

14

15

16

17

18 19

20

21 22

23

24

25

26

27

28

29

30

31

32 33 34

35

36

37

38

39

40

41

42

43

44

45

46

47 48

49

50 51

52 53

54

55

56

57

58

59

1/31/14 14:31

HOUSE BILL NO. 375

FLOOR AMENDMENT IN THE NATURE OF A SUBSTITUTE (Proposed by Delegate O'Quinn on January 28, 2014)

(Patron Prior to Substitute—Delegate O'Quinn)

A BILL to amend the Code of Virginia by adding in Title 59.1 a chapter numbered 18.1, consisting of sections numbered 59.1-215.1 through 59.1-215.5, relating to bad faith assertions of patent infringement; penalties.

Be it enacted by the General Assembly of Virginia:

1. That the Code of Virginia is amended by adding in Title 59.1 a chapter numbered 18.1, consisting of sections numbered 59.1-215.1 through 59.1-215.5, as follows:

CHAPTER 18.1.

BAD FAITH ASSERTIONS OF PATENT INFRINGEMENT.

§ 59.1-215.1. Definitions.

As used in this chapter, unless the context requires a different meaning:

"Assertion of patent infringement" means (i) sending or delivering a demand letter to a target; (ii) threatening a target with litigation asserting, alleging, or claiming that the target has engaged in patent infringement; (iii) sending or delivering a demand letter to the customers of a target; or (iv) otherwise making claims or allegations, other than those made in litigation against a target, that a target has engaged in patent infringement or that a target should obtain a license to a patent in order to avoid

"Demand letter" means a letter, email, or other communication asserting, alleging, or claiming that the target has engaged in patent infringement, or that a target should obtain a license to a patent in order to avoid litigation, or any similar assertion.

"Patent infringement" means any conduct that constitutes infringement pursuant to applicable law,

including 35 U.S.C. § 271, as amended.

"Target" means a person residing in, conducting substantial business in, or having its principal place of business in the Commonwealth and with respect to whom an assertion of patent infringement is made.

§ 59.1-215.2. Bad faith assertions of patent infringement.

A. A person shall not make, in bad faith, an assertion of patent infringement.

B. The following shall constitute indicia that a person's assertion of patent infringement was made in

1. The demand letter does not contain:

a. The number of the patent that is asserted, alleged, or claimed to have been infringed; or

b. The name and address of the patent's owner or owners and assignee or assignees, if any.

2. The person sends a demand letter to a target without first making a reasonable effort under the circumstances to conduct an analysis comparing the claims in the patent to the target's products, services, and technology, or to identify specific areas in which the products, services, or technology are covered by the claims in the patent.

3. The demand letter does not identify specific areas in which the products, services, and technology

are covered by the claims in the patent.

4. The person offers to license the patent for an amount that is not based on a reasonable estimation of the value of a license to the patent.

5. The person making an assertion of patent infringement acts in subjective bad faith, or a reasonable actor in the person's position would know or reasonably should know that such assertion is baseless.

6. The assertion of patent infringement is deceptive, or the person threatens legal action that cannot

legally be taken or that is not intended to be taken.

7. The person or its subsidiaries or affiliates have previously filed or threatened to file one or more lawsuits based on the same or similar assertion of patent infringement, the person attempted to enforce the assertion of patent infringement in litigation, and a court found the assertion to be objectively baseless or imposed sanctions for the assertion.

8. The patent alleged to be infringed was not in force at the time the allegedly infringing conduct

occurred, or the patent claims alleged to be infringed have previously been held to be invalid.

C. The following shall constitute indicia that a person's assertion of patent infringement was not made in bad faith, but the absence of such indicia shall not constitute evidence of bad faith:

1. The person engages in a reasonable effort under the circumstances to establish that the target has infringed the patent and to negotiate an appropriate remedy.

HB375H2 2 of 2

2. The person makes a substantial investment in the use of the patent or in the development, production, or sale of a product or item covered by the patent.

3. The person has:

a. Demonstrated good faith in previous efforts to enforce the patent or a substantially similar patent; or

b. Successfully enforced the patent, or a substantially similar patent, through litigation.

4. The person is an institution of higher education or a technology transfer office organization owned by or affiliated with an institution of higher education.

D. The lists of indicia in this section are non-exclusive, and all indicia need not be present for a

finding of bad faith or good faith.

§ 59.1-215.3. Enforcement; remedies; civil investigative demands; assurances of voluntary

compliance; restraining prohibited acts.

A. Whenever the Attorney General has reasonable cause to believe that any person has engaged in, or is engaging in, or is about to engage in, any violation of this chapter, the Attorney General is empowered to issue a civil investigative demand. The provisions of § 59.1-9.10 shall apply mutatis mutandis to civil investigative demands issued pursuant to this section.

B. The Attorney General or any attorney for the Commonwealth may accept an assurance of voluntary compliance with this chapter from any person subject to the provisions of this chapter. Any such assurance shall be in writing and be filed with and be subject on petition to the approval of the appropriate circuit court. Such assurance of voluntary compliance shall not be considered an admission of guilt or a violation for any purpose. Such assurance of voluntary compliance may at any time be reopened by the Attorney General or the attorney for the Commonwealth for additional orders or decrees to enforce the assurance of voluntary compliance. When an assurance is presented to the circuit court for approval, the Attorney General or the attorney for the Commonwealth shall file, in the form of a complaint, the allegations that form the basis for the entry of the assurance. The assurance may provide by its terms for any relief that an appropriate circuit court could grant, including but not limited to arbitration of disputes between a person subject to the provisions of this chapter and any targets, investigative expenses, civil penalties, and costs, provided, however, that nothing in this chapter shall be construed to authorize or require the Commonwealth, the Attorney General, or any attorney for the Commonwealth to participate in arbitration of violations under this section.

C. Notwithstanding any other provisions of law to the contrary, the Attorney General or any attorney for the Commonwealth may cause an action to be brought in the appropriate circuit court in the name of the Commonwealth to enjoin any violation of this chapter. The circuit court having jurisdiction may enjoin such violations notwithstanding the existence of an adequate remedy at law. In any action under this section, it shall not be necessary that damages be proved. Unless the Attorney General or the attorney for the Commonwealth determines that a person subject to the provisions of this chapter intends to depart from the Commonwealth or to remove his property from the Commonwealth, or to conceal himself or his property within the Commonwealth, or on a reasonable determination that irreparable harm may occur if immediate action is not taken, the Attorney General or the attorney for the Commonwealth shall, before initiating any legal proceedings as provided in this section, give notice in writing that such proceedings are contemplated and allow such person a reasonable opportunity to show that a violation did not occur or execute an assurance of voluntary compliance as provided in subsection B. The circuit courts are authorized to issue temporary or permanent injunctions to restrain and prevent violations of this chapter. The circuit court also may award to the Commonwealth a civil penalty of not more than \$2,500 for each violation, reasonable expenses incurred in investigating and preparing the case, and attorneys' fees.

D. Any person outside the Commonwealth asserting patent infringement to a target shall be deemed to be transacting business within the Commonwealth within the meaning of subdivision A 1 of \S 8.01-328.1 and shall thereby be subject to the jurisdiction of the courts of the Commonwealth.

E. Nothing in this chapter authorizes the courts of the Commonwealth, the Attorney General, or any attorney for the Commonwealth to exercise jurisdiction over a claim for relief arising under an Act of Congress relating to patents.

§ 59.1-215.4. Exemptions.

A demand letter or assertion of patent infringement that includes a claim for relief arising under 35 U.S.C. § 271(e)(2) or 42 U.S.C. § 262 shall not be subject to the provisions of this chapter. § 59.1-215.5. Severability.

If any section, subsection, sentence, part, or application of this chapter is adjudged by any court of competent jurisdiction to be invalid, such judgment shall not affect, impair or invalidate any other section, subsection, sentence, part, or application but shall be confined in its operation to the section, subsection, sentence, part, or application directly involved in the controversy in which such judgment shall have been rendered.

Gallagher, Michael

From:

Rausch, Scott

Sent:

Tuesday, February 11, 2014 3:46 PM

To:

Gallagher, Michael

Subject:

RE: Amendments to LRB 29996/1; Senate Bill 498 and Assembly Bill 656 relating to Patent

Trolls

Go with your wording, I think it works better.

Scott Rausch

Chief of Staff
Office of Senator Paul Farrow
(608) 266-9174
Scott.Rausch@legis.wi.gov

From: Gallagher, Michael

Sent: Tuesday, February 11, 2014 3:44 PM

To: Rausch, Scott

Subject: RE: Amendments to LRB 29996/1; Senate Bill 498 and Assembly Bill 656 relating to Patent Trolls

Rather than saying "owned by or affiliated with" a university, you may want to consider: "owned, controlled, or operated by, or affiliated with," a university. Let me know if you want to go with that. Otherwise, I will stick with the "owned by or affiliated with."

Thanks.

Mike

Mike Gallagher

Attorney Wisconsin Legislative Reference Bureau (608) 267-7511

From: Rausch, Scott

Sent: Tuesday, February 11, 2014 12:30 PM

To: Gallagher, Michael

Subject: RE: Amendments to LRB 29996/1; Senate Bill 498 and Assembly Bill 656 relating to Patent Trolls

Yes, if it is easier to do a sub amendment, then we can offer a substitute.

Scott Rausch

Chief of Staff
Office of Senator Paul Farrow
(608) 266-9174
Scott.Rausch@legis.wi.gov

From: Gallagher, Michael

Sent: Tuesday, February 11, 2014 12:27 PM

· To: Rausch, Scott

Subject: RE: Amendments to LRB 29996/1; Senate Bill 498 and Assembly Bill 656 relating to Patent Trolls

Okay. It looks like you want one amendment with the three exemptions, not three separate amendments, right?

Mike Gallagher Attorney Wisconsin Legislative Reference Bureau (608) 267-7511

From: Rausch, Scott

Sent: Tuesday, February 11, 2014 12:22 PM

To: Gallagher, Michael

Subject: Amendments to LRB 29996/1; Senate Bill 498 and Assembly Bill 656 relating to Patent Trolls

Michael,

We have a few amendments to the Patent Troll bill. Bear with me, there are a lot of moving parts with this request.

I have amendment requests from pharmaceutical companies, the University of Wisconsin, and Bio-tech companies. I want to ease all of their concerns.

Attached you will find a document relating to the Virginia model legislation on patent trolling. On page two, in the highlighted section, you will see the language that we believe will ease the concerns of pharmaceuticals.

UW would like an exemption as well, and the example of their request is a follows:

This would go into the new section of the draft that lays out exemptions: (1) The person is an institution of higher education or a technology transfer organization owned or affiliated with an institution of higher education.

BioForward would also like an exemption for medical devices.

The following may clear up the requests for all three:

"Exemption.—A patent notification sent by the following shall not be subject to the provisions of this Act:

- 1) A person that is an institution of higher education or a technology transfer organization owned or affiliated with an institution of higher education; or
- 2) A person sending the patent notification to a target that has filed an application to the FDA or USDA for approval of a medical device; or
- 3) A person sending the patent notification to a target for a claim for relief arising under 35 U.S.C. § 271(e)(2) or 42 U.S.C. § 262."

Sub 3 is the same language from Pharma in the attached document.

Sub 1 ensures that WARF and other public entities (like the Medical College of Wisconsin) that are held to greater levels of accountability are exempted as requested.

Sub 2 provides an exemption when the underlying patents are used in medical devices that require approval by the FDA and USDA as requested by BioForward. This language does not exempt a person from attempting to unfairly enforce the underlying patents to the extent they are NOT used in medical devices that require approval from the FDA or USDA. As an example, a patent covering a processor used in a MRI machine would be exempted when it is asserted against

another who is trying to use the same processor in an MRI to be approved by the FDA, but it would not be exempted when it is asserted against a print control system, phone, or non-medical device technology, etc.... This makes sense because of the greater level of oversight for those regulated industries like medical devices and pharmaceuticals but still protects those Wisconsin companies that are not subject to those federal requirements.

I hope this information is clear. If you have any questions please let me know. I can run your questions passed interested parties.

Thank you for your attention to these amendment requests.

Scott Rausch

Chief of Staff
Office of Senator Paul Farrow
(608) 266-9174
Scott.Rausch@legis.wi.gov

Gallagher, Michael

From:

Rausch, Scott

Sent: To: Wednesday, February 12, 2014 11:00 AM

Subject:

Gallagher, Michael FW: SB 498 amendment

Michael,

BioForward has just provided added input on their requests for the Patent Troll Bill. I hope this information provides a little more insight into what will get them to neutral on the bill.

Regards,

Scott Rausch

Chief of Staff
Office of Senator Paul Farrow
(608) 266-9174
Scott.Rausch@legis.wi.gov

From: Jordan K. Lamb [mailto:jkl@dewittross.com] Sent: Wednesday, February 12, 2014 10:58 AM

To: Henderson, Patrick

Cc: THOMAS MOORE; Rausch, Scott; Pauls, Jason

Subject: RE: SB 498 amendment

Pat, thank you for sending this. I have gone over your suggestions with a number of my board members last night and this morning. My concern is still with number (2) below. Our goal is to have our medical device companies excluded from this law the same way that you have excluded entities like WARF (number (1)) and our drug development companies (number (3)). Simply, the draft needs to exclude medical device companies from having to comply with the law for demand letters related only to patents for our FDA or UDSA approved products. I don't think (2) in your draft accomplishes that. Rather, you make the exclusion from this law contingent on whether the "target" has an FDA or USDA approved device. That seems backwards. We are the ones with the FDA/USDA approved devices and related patents. That's what makes us medical device companies.

Accordingly, I offer for your consideration a redraft of (2) as follows: (2) A person asserting a claim for relief arising out of a patent on a device, or a component of a device, that is subject to approval by FDA or USDA;

There may be statutory sections that could be cited here like you have cited for the drug development companies, but I need to talk to the medical device counsel in DC for BIO to get those. I don't know them and the patent attorney I was working with last night didn't know them well-enough to offer a list. I will look into that more.

Also, I think the drafting of number (3) is repetitive. You talk about sending the notification in the intro, so it doesn't seem to need to be restated in (3). I suggest this: (3) A person sending the patent notification to a target for asserting a claim for relief arising under 35 U.S.C. § 271(e)(2) or 42 U.S.C. § 262.

| I am still discussing this with my affected companies, but I was morning. | nted to let you know where we are this |
|---------------------------------------------------------------------------|----------------------------------------|
| Many thanks, Jordan | |
| | |

From: Henderson, Patrick [mailto:Patrick.Henderson@qg.com]

Sent: Tuesday, February 11, 2014 11:41 AM

To: Jordan K. Lamb

Cc: THOMAS MOORE; Rausch, Scott; Pauls, Jason

Subject: RE: SB 498 amendment

Hi all,

Here are our thoughts on the exemption. Our general concern is that as proposed it may go too far and exempt trolls who acquire a patent that has applicability in both medical devices and other non-medical industries. They would be able to "hide" behind the medical device applications to troll other industries. Our suggested revisions are below. We think this still accomplishes everyone's goals (Pharma, BioForward, WARF and the WI manufacturing community as a whole).

"Exemption.—A patent notification sent by the following shall not be subject to the provisions of this Act:

- 1) A person that is an institution of higher education or a technology transfer organization owned or affiliated with an institution of higher education; or
- 2) A person sending the patent notification to a target that has filed an application to the FDA or USDA for approval of a medical device; or
- 3) A person sending the patent notification to a target for a claim for relief arising under 35 U.S.C. § 271(e)(2) or 42 U.S.C. § 262."

Sub 3 is the same language for Pharma as proposed by Tom, and should be good to go.

Sub 1 ensures that WARF and other public entities (like the Medical College of Wisconsin) that are held to greater levels of accountability are exempted as requested.

Sub 2 provides an exemption when the underlying patents are used in medical devices that require approval by the FDA and USDA as requested by BioForward. This language does not exempt a person from attempting to unfairly enforce the

underlying patents to the extent they are NOT used in medical devices that require approval from the FDA or USDA. As an example, a patent covering a processor used in a MRI machine would be exempted when it is asserted against another who is trying to use the same processor in an MRI to be approved by the FDA, but it would not be exempted when it is asserted against a print control system, phone, or non-medical device technology, etc.... This makes sense because of the greater level of oversight for those regulated industries like medical devices and pharmaceuticals but still protects those Wisconsin companies that are not subject to those federal requirements.

We hope that everyone could see this as a good compromise that protects everyone's interests without leaving one industry open for abuse by Patent Trolls.

Thanks Pat

From: Jordan K. Lamb [mailto:jkl@dewittross.com]

Sent: Tuesday, February 11, 2014 9:58 AM

To: Henderson, Patrick

Cc: THOMAS MOORE; Rausch, Scott **Subject:** RE: SB 498 amendment

Hi Pat. I left you a message on your voicemail a couple of minutes ago. Will try your cell.

The following is what we are coming up with. It is aimed at protecting medical devices and tech transfer. The first red language is aimed at devices, such as those developed by GE, which have underlying IP that can include software. However, all aspects of the device are approved by either FDA or USDA. (I believe that makes them different from other software technology.)

The reference to 35 USC 200-212 in red is the Bayh-Dole Act language. It is aimed at tech transfer from universities and other research institutions.

"Exemption.—A demand letter or assertion of a patent infringement for any intellectual property that requires FDA or USDA approval or that includes a claim for relief arising under 35 U.S.C. § 271(e)(2), 35 U.S.C. § 200-212, or 42 U.S.C. § 262 shall not be subject to the provisions of this Act."

Let me know if you have any questions. Jordan

From: Henderson, Patrick [mailto:Patrick.Henderson@qg.com]

Sent: Tuesday, February 11, 2014 9:34 AM

To: Jordan K. Lamb

Cc: THOMAS MOORE; Rausch, Scott Subject: RE: SB 498 amendment

Thanks Jordan. I don't want to distract you from that effort but if you get a chance to give me a call that would be much appreciated. I'll be in the office for the next 45 minutes to an hour at 414-566-2345 and then on my cell at 608-575-8472.

Thanks

From: Jordan K. Lamb [mailto:jkl@dewittross.com]

Sent: Tuesday, February 11, 2014 9:25 AM

To: Henderson, Patrick

Cc: THOMAS MOORE; Rausch, Scott Subject: Re: SB 498 amendment

I am working on language. We probably need to add another USC citation and some narrative. I will get back to you as soon as I can. I am emailing with my board and our patent attorneys.

Sent from Jordan Lamb's iPhone

On Feb 11, 2014, at 9:08 AM, "Henderson, Patrick" < Patrick. Henderson@qg.com wrote:

How would we accomplish adding medical devises?

From: THOMAS MOORE [mailto:temoore@tmga.us]

Sent: Tuesday, February 11, 2014 9:06 AM

To: Rausch, Scott; Henderson, Patrick; Jordan K. Lamb

Subject: SB 498 amendment

Scott / Pat:

I was speaking with Jordan Lamb regarding the amendment to SB 498. While the exception for FDA approved drugs in the VA bill takes care of PhRMA's concerns, it does not speak to FDA approved DEVISES.

We would support adding language that make is clear the exception extends to FDA approved medical devises as well. This would get neutrality from both PhRMA and Bioforward.

Pat, OK by Quad? Scott, OK by your office?

Tom Moore

THOMAS E. MOORE
Thomas E. Moore Government Affairs, Inc.
22 East Mifflin Street, Suite 1010
Madison, WI 53703
(608) 294-1278
(608) 256-6222 f
(608) 335-1660 c
temoore@tmga.us

Begin forwarded message:

From: THOMAS MOORE <temoore@tmga.us>

Subject: SB 498

Date: February 10, 2014 at 1:33:45 PM CST

To: "Rausch, Scott" < Scott.Rausch@legis.wisconsin.gov > Cc: "Henderson, Patrick" < patrick.henderson@gq.com >

Scott - I wanted to confirm with you that I spoke with Pat Henderson and Quad Graphics is willing to agree to the amendment contained in this substitute amendment from the state of Virginia.

This provides an exemption for "A demand letter or assertion of patent infringement that includes a claim for relief arising under 35 U.S.C. Section 271(e)(2) or 42 U.S.C. Section 262 shall not be subject to the provision of this chapter."

If this is added to the SB 498, PhRMA will withdraw our objections and I will communicate with PhRMA members and ask for their neutrality on the bill.

Call if you have any questions.

Tom Moore for PhRMA

THOMAS E. MOORE
Thomas E. Moore Government Affairs, Inc.
22 East Mifflin Street, Suite 1010
Madison, WI 53703
(608) 294-1278
(608) 256-6222 f
(608) 335-1660 c
temoore@tmga.us

Follow Quad/Graphics in social media

IRS Circular 230 Disclosure: To comply with requirements imposed by the IRS, we inform you that any U.S. federal tax advice contained herein (including any attachments), unless specifically stated otherwise, is not intended or written to be used, and cannot be used, for the purposes of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter herein.

This message is a PRIVATE communication. This message and all attachments are a private communication sent by a law firm and may be confidential or protected by privilege. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the information contained in or attached to this message is strictly prohibited. Please notify the sender of the delivery error by replying to this message, and then delete it from your system. Thank you.

IRS Circular 230 Disclosure: To comply with requirements imposed by the IRS, we inform you that any U.S. federal tax advice contained herein (including any attachments), unless specifically stated otherwise, is not intended or written to be used, and cannot be used, for the purposes of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter herein.

| This message is a PRIVATE communication. This message and all attachments are a private communication sent by a law firm and may be confidential or protected by privilege. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the information contained in or attached to this message is strictly prohibited. Please notify the sender of the delivery error by replying to this message, and then delete it from your system. Thank you. |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ************************************** |
| This message is a PRIVATE communication. This message and all attachments are a private communication sent by a law firm and may be confidential or protected by privilege. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the information contained in or attached to this message is strictly prohibited. Please notify the sender of the delivery error by replying to this message, and then delete it from your system. Thank you. |

IN: 2/12 State of Wisconsin 2013 - 2014 LEGISLATURE




RELIMINARY DRAFT - NOT READY FOR INTRODUCTION

SENATE AMENDMENT,

TO SENATE BILL 498

Fixed request



1 At the locations indicated, amend the bill as follows: : on lines al 1. Page 3, lines 21 and 23 substitute "subsection (2)" for "this section".

2. Page 4, line 4: substitute "subsection (2)" for "this".

3. Page 4, line 5: delete "section".

4. Page 4, line 6 and 8 substitute "subsection" (2)" for "this section".

5. Page 4, line 15: after that line insert:

"(4) EXEMPTIONS. Subsection (2) does not apply to any of the following:

(a) A patent notification of an institution of higher education or of a technology transfer organization that is owned, controlled, or operated by, or affiliated with, an

institution of higher education. 10

6

8

9

(1)

12

(b) A patent notification based on a target's product, service, process, or

technology that is the subject of or a part of the target's application to the federal food

attempting to enforce or assert a vight in Connection with a patent or pending patent on a device, or a component of that device, that is subject to approval by

 \bigcirc and

and drug administration or the federal department of agriculture for approval of a

2 medical device.

3 (c) A patent notification attempting to enforce or assert a right arising under

4 35 USC 271 (e) (2) or 42 USC 262.".

5

(END)

Gallagher, Michael

From:

Rausch, Scott

Sent:

Thursday, February 13, 2014 10:30 AM

To: Subject: Gallagher, Michael RE: SB 498 amendment

Mike,

I have one change to the amendment. In Line 9 on page one, I would like the word affiliated changed to associated.

It is my understanding that such language mirrors federal law.

Thanks for your help.

Scott Rausch

Chief of Staff
Office of Senator Paul Farrow
(608) 266-9174
Scott.Rausch@legis.wi.gov

From: Gallagher, Michael

Sent: Wednesday, February 12, 2014 1:05 PM

To: Rausch, Scott

Subject: RE: SB 498 amendment

Will do.

Mike Gallagher

Attorney

Wisconsin Legislative Reference Bureau

(608) 267-7511

From: Rausch, Scott

Sent: Wednesday, February 12, 2014 12:55 PM

To: Gallagher, Michael

Subject: RE: SB 498 amendment

You may proceed now.

Scott Rausch

Chief of Staff
Office of Senator Paul Farrow
(608) 266-9174
Scott.Rausch@legis.wi.gov

From: Gallagher, Michael

Sent: Wednesday, February 12, 2014 11:33 AM

To: Rausch, Scott

Subject: RE: SB 498 amendment

Do you want me to hold off on putting this through until you get the citations to federal law that Jordan references?

Mike Gallagher Attorney Wisconsin Legislative Reference Bureau (608) 267-7511

From: Rausch, Scott

Sent: Wednesday, February 12, 2014 11:00 AM

To: Gallagher, Michael

Subject: FW: SB 498 amendment

Michael,

BioForward has just provided added input on their requests for the Patent Troll Bill. I hope this information provides a little more insight into what will get them to neutral on the bill.

Regards,

Scott Rausch

Chief of Staff
Office of Senator Paul Farrow
(608) 266-9174
Scott.Rausch@legis.wi.gov

From: Jordan K. Lamb [mailto:jkl@dewittross.com]
Sent: Wednesday, February 12, 2014 10:58 AM

To: Henderson, Patrick

Cc: THOMAS MOORE; Rausch, Scott; Pauls, Jason

Subject: RE: SB 498 amendment

Pat, thank you for sending this. I have gone over your suggestions with a number of my board members last night and this morning. My concern is still with number (2) below. Our goal is to have our medical device companies excluded from this law the same way that you have excluded entities like WARF (number (1)) and our drug development companies (number (3)). Simply, the draft needs to exclude medical device companies from having to comply with the law for demand letters related only to patents for our FDA or UDSA approved products. I don't think (2) in your draft accomplishes that. Rather, you make the exclusion from this law contingent on whether the "target" has an FDA or USDA approved device. That seems backwards. We are the ones with the FDA/USDA approved devices and related patents. That's what makes us medical device companies.

Accordingly, I offer for your consideration a redraft of (2) as follows: (2) A person asserting a claim for relief arising out of a patent on a device, or a component of a device, that is subject to approval by FDA or USDA;

There may be statutory sections that could be cited here like you have cited for the drug development companies, but I need to talk to the medical device counsel in DC for BIO to get those. I don't know them



4

7

8

10

State of Wisconsin

2013 - 2014 LEGISLATURE



SENATE AMENDMENT, TO SENATE BILL 498



- At the locations indicated, amend the bill as follows: 1
- 1. Page 3, line 21: on lines 21 and 23, substitute "sub. (2)" for "this section". 2
 - 2. Page 4, line 4: substitute "sub. (2)" for "this".
 - **3.** Page 4, line 5: delete "section".
- **4.** Page 4, line 6: on lines 6 and 8, substitute "sub. (2)" for "this section". 5
- **5.** Page 4, line 15: after that line insert: 6
 - "(4) EXEMPTIONS. Subsection (2) does not apply to any of the following:
 - (a) A patent notification of an institution of higher education or of a technology transfer organization that is owned, controlled, or operated by, or affiliated with, an institution of higher education.
- (b) A patent notification attempting to enforce or assert a right in connection 11 with a patent or pending patent on a device, or a component of that device, that is 12

4

- subject to approval by the federal food and drug administration or the federal department of agriculture.
 - (c) A patent notification attempting to enforce or assert a right arising under 35 USC 271 (e) (2) or 42 USC 262.".

5 (END)



3

5

8

9

10

11


12

State of Misconsin 2013 - 2014 LEGISLATURE



SENATE AMENDMENT, TO SENATE BILL 498





At the locations indicated, amend the bill as follows:

- 1. Page 3, line 21: on lines 21 and 23, substitute "sub. (2)" for "this section".
 - 2. Page 4, line 4: substitute "sub. (2)" for "this".
- 4 3. Rage 4, line 5: delete "section".
 - 4. Page 4, line 6: on lines 6 and 8, substitute "sub. (2)" for "this section".
- 6 Page 4, line 15: after that line insert:
- 7 "(4) EXEMPTIONS. Subsection (2) does not apply to any of the following:
 - (a) A patent notification of an institution of higher education or of a technology transfer organization that is owned, controlled, or operated by, or associated with, an institution of higher education.
 - (b) A patent notification attempting to enforce or assert a right in connection with a patent or pending patent on a device, or a component of that device, that is

2

3

4

5

- subject to approval by the federal food and drug administration or the federal department of agriculture.
 - (c) A patent notification attempting to enforce or assert a right arising under 35 USC 271 (e) (2) or 42 USC 262.".

(END)

d-note



State of Misconsin 2013 - 2014 LEGISLATURE





L'ich (X

1

3

4

5

6

7

8

9

10

11

12

13

February 18, 2014 - Offered by Representative NEYLON.

AUTHORS SUBJECT TO CHANGE

At the locations indicated, amend the bill as follows.

- 2 **1.** Page 3, line 10: after "subd. 4." insert ", if any,".✓
 - **2.** Page 3, line 17: delete lines 17 to 19 and substitute:
 - "(c) 1. If a patent notification lacks any of the information required under par.

 (a), the target may notify the person who made the patent notification that the patent notification is incomplete.
 - 2. Within 30 days after the date on which a target notifies a person under subd.

 1., the person shall provide the target with the information required under par. (a) that is necessary to complete the patent notification.".
 - 3. Page 3, line 21: delete "this section." and substitute "sub. (2) (b) or (c) 2.".
 - **4.** Page 3, line 23: delete "this section." and substitute "sub. (2) (b) or to compel a person who has violated sub. (2) (c) 2. with respect to a target to provide the target with the information specified in sub. (2) (c) 2.".



IS INSECT 1-1 MAN

LRBa1730/3dn MPG:jld:jf

DRAFTER'S NOTE FROM THE LEGISLATIVE REFERENCE BUREAU

date

Senator Farrow:

This amendment incorporates AA 2 to AB 656.

Please let me know if you have any questions.

Thank you.

Michael Gallagher Legislative Attorney Phone: (608) 267–7511

E-mail: michael.gallagher@legis.wisconsin.gov

DRAFTER'S NOTE FROM THE LEGISLATIVE REFERENCE BUREAU

LRBa1730/3dn MPG:jld:rs

February 19, 2014

Senator Farrow:

This amendment incorporates AA 2 to AB-656.

Please let me know if you have any questions.

Thank you.

Michael Gallagher Legislative Attorney Phone: (608) 267–7511

E-mail: michael.gallagher@legis.wisconsin.gov